Lincoln Journal Star

Lincoln Journal Star
Share

Lincoln Journal Star

 •  March 25

Healthcare conglomerate Johnson & Johnson (NYSE: JNJ) is about as steady as they come for investors. Its more than 250 subsidiaries and three primary operating segments -- consumer health products, medical devices, and pharmaceuticals -- each come together to form one perfect puzzle for J&J, which has allowed the company to increase its dividend...

Lincoln Journal Star

 •  February 26

Carl Icahn didn't amass a net worth of an estimated $16.6 billion by making dumb moves. So when Dow Jones reported that the billionaire bought a stake in Bristol-Myers Squibb (NYSE: BMY), it captured the attention of the investment community. What potential does Icahn see in the big pharma stock? And should you consider buying Bristol-Myers Squibb...

Lincoln Journal Star

 •  February 18

If you're looking for high-quality dividend stocks that pay a better-than-average yield, the pharmaceutical industry is definitely worth checking out. Because of the political turmoil surrounding drug prices, after all, numerous pharma stocks are presently trading at extremely attractive price-to-sales and price-to-earnings ratios. The pharma...